approached significancep = 0.053
In LOCRC, MTOR mutations were significantly reduced in the treated group (4.5%) versus untreated (7.8%, p = 0.007), and AKT2 mutations approached significance (0.7% vs. 1.8%, p = 0.053).
In LOCRC, MTOR mutations were significantly reduced in the treated group (4.5%) versus untreated (7.8%, p = 0.007), and AKT2 mutations approached significance (0.7% vs. 1.8%, p = 0.053).